A multicenter real-world study of bevacizumab in heavily pretreated malignant gliomas: clinical benefit is a plausible end point?
Future Oncol
; 15(15): 1717-1727, 2019 May.
Article
en En
| MEDLINE
| ID: mdl-30977687
ABSTRACT
Aim:
This multicenter, retrospective study evaluates the clinical benefit (CB) of bevacizumab, alone or in combination, in recurrent gliomas (RG). Patients &methods:
The CB was measured as a reduction of corticosteroid dosage and an improvement ≥20 points in the Karnofsky Performance Status lasting ≥3 months.Results:
We collected data of 197 RG patients. A CB was observed in 120, patients without significant differences between patients treated with bevacizumab alone or in combination. The rate of patients who achieved a CB and free from progression at 1 year was 21.5 versus 1.4% in patients who did not report CB.Conclusion:
The majority of RG patients treated with bevacizumab reported CB. Moreover, patients with CB showed improved survival.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Bevacizumab
/
Antineoplásicos Inmunológicos
/
Glioma
Tipo de estudio:
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Límite:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Future Oncol
Año:
2019
Tipo del documento:
Article
País de afiliación:
Italia